Annovis Bio's first quarter of fiscal 2026 was a clinical-operations story that ran straight into a balance-sheet story it could not pay for. Research and development expense rose to $16.7 million from $5.0 million in the year-ago quarter as the pivotal Phase 3 Alzheimer's trial in buntanetap accelerated through its 850-patient enrollment. By the time the period closed, cash and cash equivalents had fallen to $14.2 million, total stockholders' equity had collapsed to $3.1 million, and management wrote an explicit going-concern paragraph into the same quarterly filing. Two months after quarter-end, on July 7, 2026, the company announced it had fully enrolled 850 patients at 83 U.S. sites - the largest single milestone in the company's history. The trial is enrolled. The runway behind it is not. Three underwritten financings and one at-the-market tap closed between April 10 and May 21, 2026, generating roughly $25 million of gross proceeds and pushing the share count from 28.5 million at March 31 to 34.6 million at the May 15 cover and approximately 42.5 million after the May 20 public offering. At a reference price of $1.79 on August 13, 2026, Annovis trades at a market value of roughly $76 million, with another 18.2 million warrants outstanding at strikes of $2.20 to $9.00 - all above the current price and all out-of-the-money.
The two paths diverge sharply over the next five quarters. Management has scheduled the six-month symptomatic data readout for Q1 2027 and the eighteen-month disease-modifying data readout for Q1 2028, with two separate New Drug Application submissions to follow each readout. The full-enrollment announcement moved the trial onto a hard timeline for the first time. It also exposed the financing gap: the same May 2026 press release disclosed that the company had agreed to engage the FDA "shortly after each respective readout," not before. The cash that funded Q1 enrollment was the cash that needs to fund Phase 3 completion, the open-label Parkinson's extension, the Parkinson's-dementia study, and the run-up to the first NDA. That is at least four years of clinical burn. Management has guided that current cash plus committed financings would fund operations only into the fourth quarter of 2026 - before the symptomatic topline, before the disease-modifying topline, before either NDA. The story is binary: a positive six-month readout in early 2027 unlocks everything; another financing window before then decides whether the company reaches that readout at all.